Monica B. Jimenez‐Castro, Arani Casillas‐Ramirez, Marta Massip‐Salcedo, Maria Elias‐Miro, Anna Serafin, Antoni Rimola, Juan Rodes, Carmen Peralta – 10 June 2011 – Numerous steatotic livers are discarded as unsuitable for transplantation (TR) because of their poor tolerance of ischemia/reperfusion (I/R). Cyclic adenosine 3′,5′‐monophosphate (cAMP)–elevating agents protect against I/R injury both in nonsteatotic livers that have been removed from non–heart‐beating donors and subjected to warm ischemia or cold ischemia (CIS) and in perfused, isolated livers.

James A. Thomas, John P. Iredale, Stuart J. Forbes – 10 June 2011

Maria Elias‐Miro, Marta Massip‐Salcedo, Monica Jimenez‐Castro, Carmen Peralta – 10 June 2011 – Strategies for improving the viability of steatotic donor livers could increase the number of organs suitable for transplantation. There is evidence that adiponectin, the most abundant adipose‐specific adipokine, acts as an anti‐obesity and anti‐inflammatory hormone. Here we review the signaling pathways of adiponectin and the possible therapies based on adiponectin regulation that have been examined or applied clinically.

Kim M. Olthoff, Alejandro Forner, Stefan Hübscher, John Fung – 7 June 2011

Clifford S. Guy, Sherri L. Rankin, Tomasz I. Michalak – 7 June 2011 – It has been recently identified that hepatocytes can act as cytotoxic effectors and can kill contacted cells by way of CD95 ligand–CD95 and perforin‐dependent pathways. However, it remained unknown whether hepatocyte‐mediated cell killing is indiscriminant or is directed toward targets with particular cell surface characteristics, as well as whether hepatocytes have the capacity to directly eliminate contacted lymphocytes.

Sophie Lotersztajn, Fatima Teixeira‐Clerc, Vanessa Deveaux, Sylvie Manin, Ariane Mallat – 7 June 2011

Isabel Campos‐Varela, Lluís Castells, Cristina Dopazo, Mercedes Pérez‐Lafuente, Helena Allende, Oscar Len, Lluís Llopart, Victor Vargas, Ramón Charco – 7 June 2011 – Sinusoidal obstruction syndrome (SOS) is a rare, life‐threatening clinical syndrome resulting from sinusoidal congestion, and it is characterized by hepatomegaly, ascites, weight gain, and jaundice. The frequency of this condition after liver transplantation (LT) is low, but when SOS is severe and refractory to medical therapy, the ultimate solution is retransplantation.

Evangelos Cholongitas, John Goulis, Evangelos Akriviadis, Geore V. Papatheodoridis – 7 June 2011 – A combination of hepatitis B immunoglobulin (HBIG) and nucleos(t)ide analogues (NUCs) is currently recommended as prophylaxis against the recurrence of hepatitis B virus (HBV) after liver transplantation (LT), but the optimal protocol is a matter of controversy. The aim of this study was the identification of factors associated with post‐LT HBV recurrence in patients receiving HBIG and NUCs.

Elizabeth A. Pomfret, J. Peter A. Lodge, Federico G. Villamil, Mark Siegler – 7 June 2011

James R. Rodrigue, Douglas W. Hanto, Michael P. Curry – 7 June 2011 – Patient‐reported outcomes are important to consider when the relative success of liver transplantation (LT) is being evaluated. Our primary objective was to examine the expectations for LT and the criteria for its success across 4 domains of functioning (pain, fatigue, emotional distress, and interference with daily activities) from the perspective of patients who were wait‐listed for LT.